Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
5.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

7.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.

JAMA oncology·2026
Same author

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Cancer treatment reviews·2026
Same author

Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].

Experimental and molecular pathology·2026

Related Experiment Video

Updated: May 6, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K

HER2 and lung cancer.

Lorenza Landi1, Federico Cappuzzo

  • 1Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, viale Alfieri 36, 57100 Livorno, Italy.

Expert Review of Anticancer Therapy
|October 19, 2013
PubMed
Summary

Human Epidermal Growth Factor Receptor 2 (HER2) deregulation in non-small-cell lung cancer (NSCLC) is under investigation. This review explores HER2

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small-cell lung cancer (NSCLC) treatment has advanced with targeted therapies for specific driver mutations like EGFR and ALK.
  • Human Epidermal Growth Factor Receptor 2 (HER2) is a known prognostic and predictive biomarker in breast cancer.
  • The role of HER2 deregulation (overexpression, amplification, mutation) in NSCLC as a therapeutic biomarker is currently undefined.

Purpose of the Study:

  • To review the prognostic and predictive impact of HER2 deregulation in NSCLC.
  • To discuss the clinical implications of targeting HER2 in NSCLC patients.

Main Methods:

  • Literature review of studies on HER2 deregulation in NSCLC.
  • Analysis of existing data on HER2 mutations, overexpression, and amplification.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

919

Related Experiment Videos

Last Updated: May 6, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

919
  • Evaluation of clinical outcomes associated with anti-HER2 therapies in NSCLC.

    • Main Results:

    • Growing interest in HER2 mutations in NSCLC, with preliminary retrospective studies suggesting potential clinical relevance.
    • HER2 deregulation, while described in NSCLC, lacks a defined role as a predictive biomarker compared to its established role in breast cancer.

    Conclusions:

    • Further research is needed to clarify the prognostic and predictive value of HER2 alterations in NSCLC.
    • The clinical utility of anti-HER2 therapies in NSCLC warrants further investigation and validation.